Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: A potentially serious diagnostic pitfall

Modern Pathology

Volumn 21, Issue 7, 2008, Pages 795-806

  Bahrami, Armita ^a   Gown, Allen M ^b   Baird, Geoffrey S ^b   Hicks, M John ^a   Folpe, Andrew L ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PHENOPATH LABORATORIES   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Alveolar rhabdomyosarcoma; Chromogranin A; Cytokeratins; Immunohistochemistry; Molecular genetics; Synaptophysin

Indexed keywords

ANTIBODY; CD56 ANTIGEN; CHROMOGRANIN A; CYTOKERATIN; SYNAPTOPHYSIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MALE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA;

ADOLESCENT; ADULT; ANTIGENS, CD56; CHILD; CHILD, PRESCHOOL; CHROMOGRANIN A; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; FEMALE; HUMANS; INFANT; KERATINS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA, ALVEOLAR; SYNAPTOPHYSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 46049120027     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.86     Document Type: Article

References (71)

1. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors, 4th edn. Mosby: St Louis, 2001.
2. Fletcher CDM, Unni KK, Mertens F, et al. Pathology and genetics of tumours of soft tissue and bone. IARC Press: Lyon, 2002.
3. Enzinger FM, Shiraki M. Alveolar rhabdomyosarcoma. An analysis of 110 cases. Cancer 1969;24:18-31.
4. Caillaud JM, Gerard-Marchant R, Marsden HB, et al. Histopathological classification of childhood rhabdomyosarcoma: a report from the International Society of Pediatric Oncology pathology panel. Med Pediatr Oncol 1989;17:391-400.
5. Newton Jr WA, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer 1995;76:1073-1085.
6. Tsokos M, Webber BL, Parham DM, et al. Rhabdomyosarcoma. A new classification scheme related to prognosis [see comments]. Arch Pathol Lab Med 1992;116:847-855.
7. Callender TA, Weber RS, Janjan N, et al. Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children. Otolaryngol Head Neck Surg 1995;112:252-257.
8. Ahmed AA, Tsokos M. Sinonasal rhabdomyosarcoma in children and young adults. Int J Surg Pathol 2007;15:160-165.
9. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol 2001;14:506-514.
10. Parham DM, Shapiro DN, Downing JR, et al. Solid alveolar rhabdomyosarcomas with the t(2;13). Report of two cases with diagnostic implications. Am J Surg Pathol 1994;18:474-478.
11. Chiles MC, Parham DM, Qualman SJ, et al. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group. Pediatr Dev Pathol 2004;7:583-594.
12. Folpe AL, McKenney JK, Bridge JA, et al. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma. Am J Surg Pathol 2002;26:1175-1183.
13. Cessna MH, Zhou H, Perkins SL, et al. Are Myogenin and MyoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 2001;25:1150-1157.
14. Mentzel T, Katenkamp D. Sclerosing, pseudovascular rhabdomyosarcoma in adults. Clinicopathological and immunohistochemical analysis of three cases. Virchows Arch 2000;436:305-311.
15. Dias P, Chen B, Dilday B, et al. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 2000;156:399-408.
16. Cui S, Hano H, Harada T, et al. Evaluation of new monoclonal anti-MyoD1 and anti-myogenin antibodies for the diagnosis of rhabdomyosarcoma. Pathol Int 1999;49:62-68.
17. Rubin BP, Hasserjian RP, Singer S, et al. Spindle cell rhabdomyosarcoma (so-called) in adults: report of two cases with emphasis on differential diagnosis. Am J Surg Pathol 1998;22:459-464.
18. Engel ME, Mouton SC, Emms M. Paediatric rhabdomyosarcoma: MyoD1 demonstration in routinely processed tissue sections using wet heat pretreatment (pressure cooking) for antigen retrieval. J Clin Pathol 1997;50:37-39.
19. Coffin CM, Rulon J, Smith L, et al. Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis. Mod Pathol 1997;10:1175-1187.
20. Hollowood K, Fletcher CD. Rhabdomyosarcoma in adults. Semin Diagn Pathol 1994;11:47-57.
21. Cavazzana AO, Schmidt D, Ninfo V, et al. Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma. Am J Surg Pathol 1992;16:229-235.
22. Seidal T, Angervall L, Kindblom LG. Expression of muscle-specific actins and myosin in light microscopically undifferentiated small and dark cell malignancies of soft tissues. APMIS 1990;98:1105-1112.
23. Jones H, Steart PV, Du Boulay CE, et al. Alpha-smooth muscle actin as a marker for soft tissue tumours: a comparison with desmin. J Pathol 1990;162:29-33.
24. Fisher C. The value of electronmicroscopy and immunohistochemistry in the diagnosis of soft tissue sarcomas: a study of 200 cases. Histopathology 1990;16:441-454.
25. Dias P, Parham DM, Shapiro DN, et al. Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol 1990;137:1283-1291.
26. Carter RL, Jameson CF, Philp ER, et al. Comparative phenotypes in rhabdomyosarcomas and developing skeletal muscle. Histopathology 1990;17:301-309.
27. Miettinen M, Rapola J. Immunohistochemical spectrum of rhabdomyosarcoma and rhabdomyosarcoma-like tumors. Expression of cytokeratin and the 68-kD neurofilament protein. Am J Surg Pathol 1989;13:120-132.
28. Seidal T, Kindblom LG, Angervall L. Myoglobin, desmin and vimentin in ultrastructurally proven rhabdomyomas and rhabdomyosarcomas. An immunohistochemical study utilizing a series of monoclonal and polyclonal antibodies. Appl Pathol 1987;5:201-219.
29. Brooks JJ. Immunohistochemistry of soft tissue tumors. Myoglobin as a tumor marker for rhabdomyosarcoma. Cancer 1982;50:1757-1763.
30. Folpe AL. MyoD1 and Myogenin Expression in Human Neoplasia: a review and update. Adv Anat Pathol 2002;9:198-203.
31. Wang NP, Marx J, McNutt MA, et al. Expression of myogenic regulatory proteins (myogenin and MyoD1) in SRCT of childhood. Am J Surg Pathol 1995;147:1799-1810.
32. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002;20:2672-2679.
33. Barr FG, Smith LM, Lynch JC, et al. Examination of Gene Fusion Status in Archival Samples of Alveolar Rhabdomyosarcoma Entered on the Intergroup Rhabdomyosarcoma Study-III Trial: a Report from the Children0s Oncology Group. J Mol Diagn 2006;8:202-208.
34. Nishio J, Althof PA, Bailey JM, et al. Use of a novel FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of alveolar rhabdomyosarcoma. Lab Invest 2006;86:547-556.
35. Miettinen M, Lehto VP, Badley RA, et al. Alveolar rhabdomyosarcoma. Demonstration of the muscle type of intermediate filament protein, desmin, as a diagnostic aid. Am J Pathol 1982;108:246-251.
36. Seidal T, Kindblom LG, Angervall L. Alveolar and poorly differentiated rhabdomyosarcoma. A clinicopathologic, light-microscopic, ultrastructural and immunohistochemical analysis. APMIS 1988;96:825-838.
37. Tsokos M. The diagnosis and classification of childhood rhabdomyosarcoma. Semin Diagn Pathol 1994;11:26-38.
38. Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol 2005;29:1025-1033.
39. Folpe AL, Weiss SW. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic study of 70 cases with emphasis on atypical and malignant variants. Am J Surg Pathol 2003;27:421-431.
40. Fanburg-Smith JC, Miettinen M. Angiomatoid 'malignant' fibrous histiocytoma: a clinicopathologic study of 158 cases and further exploration of the myoid phenotype. Hum Pathol 1999;30:1336-1343.
41. Gray MH, Rosenberg AE, Dickersin GR, et al. Cytokeratin expression in epithelioid vascular neoplasms. Hum Pathol 1990;21:212-217.
42. Tauchi K, Tsutsumi Y, Yoshimura S, et al. Immunohistochemical and immunoblotting detection of cytokeratin in smooth muscle tumors. Acta Pathol Jpn 1990;40:574-580.
43. Gu M, Antonescu CR, Guiter G, et al. Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol 2000;24:410-416.
44. Fanburg-Smith JC, Majidi M, Miettinen M. Keratin expression in schwannoma: a study of 115 retroperitoneal and 22 peripheral schwannomas. Mod Pathol 2006;19:115-121.
45. Ordonez NG. Desmoplastic small round cell tumor: II. an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am J Surg Pathol 1998;22:1314-1327.
46. Sredni ST, Neves JI, de Camargo B, et al. Pancytokeratin immunoexpression in Wilms' tumors: a simple approach for understanding tumor epithelial differentiation. Sao Paulo Med J 2004;122:181-183.
47. Collini P, Sampietro G, Bertulli R, et al. Cytokeratin immunoreactivity in 41 cases of ES/PNET confirmed by molecular diagnostic studies. Am J Surg Pathol 2001;25:273-274.
48. Coindre JM, de Mascarel A, Trojani M, et al. Immunohistochemical study of rhabdomyosarcoma. Unexpected staining with S100 protein and cytokeratin. J Pathol 1988;155:127-132.
49. Lloyd RV. Practical markers used in the diagnosis of neuroendocrine tumors. Endocr Pathol 2003;14:293-301.
50. Miettinen MM. Diagnostic soft tissue pathology. Churchill Livingstone: New York, 2003.
51. Shanfeld RL, Edelman J, Willis JE, et al. Immunohistochemical analysis of neural markers in peripheral primitive neuroectodermal tumors (pPNET) without light microscopic evidence of neural differentiation. Appl Immunohistochem 1997;5:78-86.
52. Oliveira AM, Sebo TJ, McGrory JE, et al. Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and ploidy analysis of 23 cases. Mod Pathol 2000;13:900-908.
53. Goh YW, Spagnolo DV, Platten M, et al. Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immunoultrastructural study indicating neuroendocrine differentiation. Histopathology 2001;39:514-524.
54. Eyden B, Pandit D, Banerjee SS. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases. Histopathology 2005;47:402-409.
55. Leroy X, Petit ML, Fayoux P, et al. Aberrant diffuse expression of synaptophysin in a sinonasal alveolar rhabdomyosarcoma. Pathology 2007;39:275-276.
56. Cunningham BA, Hemperly JJ, Murray BA, et al. Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science 1987;236:799-806.
57. Edelman GM. Cell adhesion molecules in the regulation of animal form and tissue pattern. Annu Rev Cell Biol 1986;2:81-116.
58. Shipley WR, Hammer RD, Lennington WJ, et al. Paraffin immunohistochemical detection of CD56, a useful marker for neural cell adhesion molecule (NCAM), in normal and neoplastic fixed tissues. Appl Immunohistochem 1997;5:87-93.
59. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997;89:4501-4513.
60. Lanier LL, Le AM, Civin CI, et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-4486.
61. Mechtersheimer G, Staudter M, Moller P. Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors. Cancer Res 1991;51:1300-1307.
62. Miettinen M, Cupo W. Neural cell adhesion molecule distribution in soft tissue tumors. Hum Pathol 1993;24:62-66.
63. Garin-Chesa P, Fellinger EJ, Huvos AG, et al. Immunohistochemical analysis of neural cell adhesion molecules. Differential expression in small round cell tumors of childhood and adolescence. Am J Pathol 1991;139:275-286.
64. Folpe AL, Schmidt RA, Chapman D, et al. Poorly differentiated synovial sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol 1998;22:673-682.
65. Lae ME, Roche PC, Jin L, et al. Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am J Surg Pathol 2002;26:823-835.
66. Stevenson A, Chatten J, Bertoni F, et al. CD99 (p30/32MIC2) Neuroectodermal/Ewing's sarcoma antigen as an immunohistochemical marker. Review of more than 600 tumors and the literature experience. Appl Immunohistochem 1994;2:231-240.
67. Rossi S, Orvieto E, Furlanetto A, et al. Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod Pathol 2004;17:547-552.
68. Folpe AL, Hill CE, Parham DM, et al. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol 2000;24:1657-1662.
69. de Alava E, Pardo J. Ewing tumor: tumor biology and clinical applications. Int J Surg Pathol 2001;9:7-17.
70. Eusebi V, Damiani S, Pasquinelli G, et al. Small cell neuroendocrine carcinoma with skeletal muscle differentiation: report of three cases. Am J Surg Pathol 2000;24:223-230.
71. Roncaroli F, Montironi R, Feliciotti F, et al. Sarcomatoid carcinoma of the anorectal junction with neuroendocrine and rhabdomyoblastic features. Am J Surg Pathol 1995;19:217-223.